{"denoms":[{"counts":[{"groupId":"BG000","value":"27"}],"units":"Participants"}],"groups":[{"description":"Adjuvant Radiation Therapy \"Sandwiched\" between Ifosfamide in Patients with Mixed Mesodermal Tumors\n\nRadiation Therapy : Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IVSS bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333mg/IVSS bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles.\n\nIfosfamide : Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IVSS bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333mg/IVSS bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles.","id":"BG000","title":"Chemotherapy and Radiation Therapy"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"15","value":"65"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Total Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Total Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Total Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Total Stage IV"}],"description":"Federation of Gynecology and Obstetrics (FIGO) is a system for staging gynecologic cancer.\n\nI Malignancy of one (Ia) or both (Ib) ovaries, without ascites; 5-year survival: 60%\n\nII Malignancy of one (IIa) or both (IIb) ovaries, with pelvic extension and ascites; 5-year survival: 40%\n\nIII Malignancy involves one/both ovaries, intraperitoneal metastases outside pelvis and/or positive retroperitoneal lymph nodes; 5-year survival: 5%\n\nIV Involvement of one/both ovaries with metastases and histologically confirmed extension to pleural cavity or liver; 5-year survival, 3%","paramType":"COUNT_OF_PARTICIPANTS","title":"FIGO Staging","unitOfMeasure":"Participants"}]}